Key facts
- Avava’s last known valuation is $48.8M (Feb 2026).
- It has raised $85.6M; the latest was Later Stage VC ($19.6M) in Feb 2026.
- Notable investors include Catalio Capital Management, Craig Drill, Jeisys Medical.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Avava
- ·The full record, as it builds
Funding rounds
No funding rounds for Avava are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Avava
Developer of 3D precision laser treatment technology designed to rejuvenate skin color. The company's treatment technology looks after melasma and post-inflammatory hyperpigmentation problems, enabling healthcare providers to offer tissue treatments to their patients.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2016
- Employees
- 66
- Website
- avavaskin.com/
- Ownership
- Privately Held (backing)
Avava doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avava shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avava in its N-PORT filings yet. We sweep new filings monthly.